TGTX vs. BGNE, SMMT, MRNA, GMAB, VTRS, ITCI, CTLT, RDY, PCVX, and SRPT
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include BeiGene (BGNE), Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
TG Therapeutics vs.
BeiGene (NASDAQ:BGNE) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
TG Therapeutics received 111 more outperform votes than BeiGene when rated by MarketBeat users. Likewise, 76.33% of users gave TG Therapeutics an outperform vote while only 68.98% of users gave BeiGene an outperform vote.
In the previous week, TG Therapeutics had 2 more articles in the media than BeiGene. MarketBeat recorded 3 mentions for TG Therapeutics and 1 mentions for BeiGene. TG Therapeutics' average media sentiment score of 0.49 beat BeiGene's score of 0.40 indicating that TG Therapeutics is being referred to more favorably in the news media.
BeiGene currently has a consensus price target of $253.69, indicating a potential upside of 0.00%. TG Therapeutics has a consensus price target of $40.67, indicating a potential upside of 28.29%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than BeiGene.
48.5% of BeiGene shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 7.4% of BeiGene shares are held by insiders. Comparatively, 10.5% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
BeiGene has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500.
TG Therapeutics has a net margin of -5.42% compared to BeiGene's net margin of -25.94%. TG Therapeutics' return on equity of -8.32% beat BeiGene's return on equity.
TG Therapeutics has lower revenue, but higher earnings than BeiGene. TG Therapeutics is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.
Summary
TG Therapeutics beats BeiGene on 14 of the 17 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TGTX) was last updated on 2/1/2025 by MarketBeat.com Staff
Free TGTX Stock Alerts